Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Liangang, Liu"'
Autor:
Fan Wu, Liangang Liu, Allison Gaudy, Xiaomin Wang, Leon Carayannopoulos, Michael Pourdehnad, Manisha Lamba
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 10, Pp 1473-1484 (2023)
Abstract Mezigdomide is a novel cereblon E3 ligase modulator (CELMoD) agent with enhanced autonomous cell‐killing activity in multiple myeloma (MM) cells, and promising immunomodulatory and antitumor activity in patients with MM. We developed a pop
Externí odkaz:
https://doaj.org/article/5d63ad4a03fa4278911b0cebdeda83b3
Autor:
Ki Young Huh, Yewon Choi, Jim Nissel, Maria Palmisano, Xiaomin Wang, Liangang Liu, Francisco Ramirez‐Valle, Howard Lee
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 4, Pp 1505-1511 (2021)
Abstract We performed a two‐part study to evaluate the pharmacokinetics, safety, and tolerability of oral apremilast, a phosphodiesterase 4 inhibitor indicated for the treatment of psoriasis, in healthy Korean adult men. In part 1, there were 12 su
Externí odkaz:
https://doaj.org/article/d3a249cc33ad4d829affa9ac366fadcf
Autor:
Ying, Ye, Allison, Gaudy, Michael, Thomas, Josephine, Reyes, Barbara, Burkhardt, Gerald, Horan, Liangang, Liu, Jian, Chen, Atalanta, Ghosh, Leonidas N, Carayannopoulos, Daniel A, Tatosian, Maria, Palmisano
Publikováno v:
Clinical Pharmacology in Drug Development. 11:1394-1404
CC-90001 selectively inhibits c-Jun N-terminal kinase (JNK), a stress-activated protein implicated in fibrosis. In 3 phase 1 trials evaluating CC-90001 pharmacokinetics, pharmacodynamics, and safety, healthy adults (N = 184) received oral CC-90001 in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9e76922352cef31abbd395278d3c483
https://doi.org/10.1002/cpdd.1178
https://doi.org/10.1002/cpdd.1178
Autor:
Yiming Cheng, Allison Gaudy, Liangang Liu, Ying Ye, Michael Thomas, Yongjun Xue, Simon Zhou, Yan Li
Publikováno v:
Clinical Pharmacology in Drug Development.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::782eb818a2323d81711f68b817d683e0
https://doi.org/10.1002/cpdd.1254
https://doi.org/10.1002/cpdd.1254
Autor:
Michael Thomas, Maria Palmisano, Mark Thomas, Sekhar Surapaneni, Yongjun Xue, Mary Liu, Simon Zhou, Rebecca N. Wood-Horrall, Gopal Krishna, Liangang Liu, Leonidas N Carayannopoulos, Ken Ogasawara
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:941-952
Fedratinib, an oral, selective Janus kinase 2 inhibitor, has been shown to inhibit P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion transporting polypeptide (OATP) 1B1, OATP1B3, organic cation transporter (OCT) 2, and mul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d770833137270f254670e8ca5601cb8
https://doi.org/10.1007/s00280-021-04346-7
https://doi.org/10.1007/s00280-021-04346-7
Autor:
Yongjun Xue, Sekhar Surapaneni, Mark Thomas, Gopal Krishna, Leonidas N Carayannopoulos, Simon Zhou, Mary Liu, Jeanelle Kam, Liangang Liu, Ken Ogasawara, Maria Palmisano
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:369-377
Fedratinib is an oral and selective Janus kinase 2 inhibitor that is indicated for treatment of adults with intermediate-2 or high-risk primary or secondary myelofibrosis. Fedratinib is metabolized by cytochrome P450s (CYPs), primarily CYP3A4. The ob
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::417c826164b7422aa497fea66d144d4b
https://doi.org/10.1007/s00280-021-04292-4
https://doi.org/10.1007/s00280-021-04292-4
Autor:
Liangang Liu, Howard Lee, Jim Nissel, Xiaomin Wang, Yewon Choi, Francisco Ramirez-Valle, Ki Young Huh, Maria Palmisano
Publikováno v:
Clinical and Translational Science
Clinical and Translational Science, Vol 14, Iss 4, Pp 1505-1511 (2021)
Clinical and Translational Science, Vol 14, Iss 4, Pp 1505-1511 (2021)
We performed a two‐part study to evaluate the pharmacokinetics, safety, and tolerability of oral apremilast, a phosphodiesterase 4 inhibitor indicated for the treatment of psoriasis, in healthy Korean adult men. In part 1, there were 12 subjects wh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d79bd338771ef7683746c6dfd862a15f
http://europepmc.org/articles/PMC8301552
http://europepmc.org/articles/PMC8301552
Autor:
Yizhe Chen, Ken Ogasawara, Rebecca Wood-Horrall, Mark Thomas, Michael Thomas, Bing He, Liangang Liu, Yongjun Xue, Sekhar Surapaneni, Leonidas N. Carayannopoulos, Simon Zhou, Maria Palmisano, Gopal Krishna
Publikováno v:
Cancer chemotherapy and pharmacology. 90(4)
Purpose Fedratinib is an orally administered Janus kinase (JAK) 2–selective inhibitor for the treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis. In vitro, fedratinib is predominantly metabolized by cyto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91ab1303424f2538574182d7f8ba74c2
https://pubmed.ncbi.nlm.nih.gov/36001108
https://pubmed.ncbi.nlm.nih.gov/36001108
Publikováno v:
Journal of clinical pharmacy and therapeuticsREFERENCES. 47(8)
CC-292 is a potent, selective, orally administered small molecule inhibitor of bruton tyrosine kinase (BTK). The aim of this study was to evaluate the relative bioavailability of newly developed CC-292 tablet formulation (P22 tablet (P22-TAB) and CC-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf36797873ba6a1f848e95a48bb7a58a
https://pubmed.ncbi.nlm.nih.gov/35307850
https://pubmed.ncbi.nlm.nih.gov/35307850
Autor:
Jian Chen, Maria Palmisano, Yan Li, Liangang Liu, Kimberly MacGorman, Matthew Hoffmann, Simon Zhou
Publikováno v:
Clinical Pharmacology in Drug Development. 9:785-796
CC-122 (Avadomide) is a nonphthalimide analogue of thalidomide that has multiple pharmacological activities including immune modulation of several immune cell subsets, antigrowth activity, antiproliferative activity, and antiangiogenic activity. CC-1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42292c74cd5473687bbc2095906d3507
https://doi.org/10.1002/cpdd.760
https://doi.org/10.1002/cpdd.760